Efficacy and time to next treatment following lenalidomide/rituximab (R-2) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT).-MedSci.cn

Efficacy and time to next treatment following lenalidomide/rituximab (R-2) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT).

Gribben, JG; Izutsu, K; Fowler, NH; Hong, XN; Zhang, HL; Offner, F; Scheliga, AAS; Nowakowski, GS; Pinto, A; Re, F; Fogliatto, LM; Scheinberg, P; Flinn, I; Moreira, C; Kalambakas, SA; Fustier, P; Wu, CQ; Leonard, JP

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):

科室
- - 订阅+
  - 更多科室
工具
服务